CAN-2409 Phase 3 Data Published in Lancet Oncology, Showing Significant DFS Improvement
Summary
Candel Therapeutics announced the publication of its pivotal Phase 3 clinical trial data for CAN-2409 in localized prostate cancer in The Lancet Oncology. The publication confirms a 30% improvement in disease-free survival (DFS) and a 38% improvement in prostate cancer-specific DFS. This follows previous announcements of positive Phase 3 data in March and May, and a commercialization agreement in April. The peer-reviewed publication in a high-impact journal provides significant external validation for the drug's efficacy and safety profile, strengthening the company's path towards potential regulatory approval and commercialization.
At the time of this announcement, CADL was trading at $8.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $623.5M. The 52-week trading range was $4.35 to $9.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.